Hyloris Pharmaceuticals SA (HYL.BR)
EUR 5.8
(-1.36%)
EUR 5.8
(-1.36%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.08 Million EUR | -29.28% |
| 2022 | 2.95 Million EUR | -4.68% |
| 2021 | 3.09 Million EUR | 1669.14% |
| 2020 | 175 Thousand EUR | 92.31% |
| 2019 | 91 Thousand EUR | 0.0% |
| 2018 | 91 Thousand EUR | -57.28% |
| 2017 | 213 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q2 | 580 Thousand EUR | 0.0% |
| 2023 Q3 | 1.52 Million EUR | 163.28% |
| 2023 Q1 | 580 Thousand EUR | -14.33% |
| 2023 FY | 2.08 Million EUR | -29.28% |
| 2023 Q4 | 1.52 Million EUR | 0.0% |
| 2022 Q2 | 1.03 Million EUR | 100.0% |
| 2022 FY | 2.95 Million EUR | -4.68% |
| 2022 Q4 | 677 Thousand EUR | 0.0% |
| 2022 Q3 | 677 Thousand EUR | -34.46% |
| 2022 Q1 | 516.49 Thousand EUR | -77.13% |
| 2021 FY | 3.09 Million EUR | 1669.14% |
| 2021 Q4 | 2.25 Million EUR | 100.0% |
| 2021 Q3 | 1.12 Million EUR | 34.73% |
| 2021 Q2 | 838 Thousand EUR | 100.0% |
| 2021 Q1 | 419 Thousand EUR | 801.08% |
| 2020 Q2 | 19 Thousand EUR | -69.84% |
| 2020 FY | 175 Thousand EUR | 92.31% |
| 2020 Q4 | 46.5 Thousand EUR | 0.0% |
| 2020 Q1 | 63 Thousand EUR | 687.5% |
| 2020 Q3 | 46.5 Thousand EUR | 144.74% |
| 2019 Q2 | 35 Thousand EUR | -12.5% |
| 2019 Q3 | 8000.00 EUR | -77.14% |
| 2019 Q1 | 40 Thousand EUR | 0.0% |
| 2019 FY | 91 Thousand EUR | 0.0% |
| 2019 Q4 | 8000.00 EUR | 0.0% |
| 2018 FY | 91 Thousand EUR | -57.28% |
| 2017 FY | 213 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 55.022% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 54.837% |
| Adocia SA | 2.15 Million EUR | 2.93% |
| Aelis Farma SA | 9.05 Million EUR | 76.949% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | 33.767% |
| genOway Société anonyme | 20.04 Million EUR | 89.589% |
| IntegraGen SA | 12.53 Million EUR | 83.354% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -595.588% |
| Neovacs S.A. | 533.41 Thousand EUR | -291.255% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -24.114% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -10442.534% |
| Sensorion SA | 4.74 Million EUR | 55.999% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -604.28% |
| TME Pharma N.V. | 17 Thousand EUR | -12176.471% |
| Valbiotis SA | 4.73 Million EUR | 55.905% |
| TheraVet SA | 1.07 Million EUR | -93.589% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -15.944% |
| argenx SE | 1.13 Billion EUR | 99.816% |
| BioSenic S.A. | 543 Thousand EUR | -284.346% |
| Celyad Oncology SA | 102 Thousand EUR | -1946.078% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 99.129% |
| Genfit S.A. | 28.56 Million EUR | 92.694% |
| GeNeuro SA | - EUR | -Infinity% |
| Innate Pharma S.A. | 51.9 Million EUR | 95.979% |
| Inventiva S.A. | 17.47 Million EUR | 88.059% |
| MaaT Pharma SA | 2.22 Million EUR | 6.329% |
| MedinCell S.A. | 9.16 Million EUR | 77.216% |
| Nanobiotix S.A. | 30.05 Million EUR | 93.057% |
| Onward Medical N.V. | 532 Thousand EUR | -292.293% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 85.294% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 6.286% |
| Oxurion NV | 263 Thousand EUR | -693.536% |
| Pharming Group N.V. | 245.31 Million EUR | 99.149% |
| Poxel S.A. | 1.98 Million EUR | -5.351% |
| GenSight Biologics S.A. | 1.26 Million EUR | -64.72% |
| Transgene SA | 1.18 Million EUR | -76.267% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.96% |
| Valneva SE | 153.71 Million EUR | 98.642% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 157.652% |